Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax Inc (NVAX) outlines its strategic focus on partnerships and pipeline expansion while navigating revenue fluctuations ...

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

Shares of Novavax Inc. NVAX shed 2.41% to $7.68 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.35% to 18,285.16 ...

Shares of Novavax Inc. NVAX climbed 17.99% to $8.33 Friday, on what proved to be an all-around favorable trading session for ...

NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...